European Small Molecule Manufacturing at Critical Juncture as Green Rules Meet Market Reality

“From Tokyo to Boston, we knew people had to see and feel the future we were building together. That is how you create lasting change.”Amber Meriwether, Director of Corporate Strategy at Astellas Pharma, has orchestrated one of the industry’s most dramatic supplier rationalisations whilst navigating complex cultural dynamics across seven global locations.In the latest PharmaSource podcast episode, Amber reveals how effective supplier rationalisation transcends traditional cost-cutting approaches, requiring sophisticated change management, cultural intelligence, and the ability to forge consensus amongst diverse scientific teams spanning multiple continents and research modalities.https://pharmasource.global/content/podcast/how-astellas-procurement-cut-their-supplier-base-by-95-while-building-global-consensus/

"Current revenue scale is $1.3 billion. We anticipate it will grow to $5 billion, just in five years' time. We've committed to invest about two-thirds of Fujifilm's entire annual capex in this business."Toshihisa “Toshi” Iida, Chairman of FUJIFILM Biotechnologies Group and Board Director at FUJIFILM Corporation, reveals how 89 years of healthcare heritage drives the company's ambitious CDMO expansion strategy.Toshihisa brings 34 years of experience at Fujifilm, having witnessed the company's transformation from the golden age of photographic film through the digital revolution to its current position as a major biotechnology manufacturer. His journey spans international marketing, European operations, and now leading the Life Sciences strategy for the 91-year-old corporation.In this exclusive podcast interview, Toshihisa explains how Fujifilm's unique modular manufacturing approach and zero-defect philosophy position the company to achieve unprecedented growth whilst delivering scalability, speed and resilience to pharmaceutical partners worldwide.Full article: https://pharmasource.global/content/podcast/from-film-to-pharma-inside-fujifilm-biotechnologies-5-billion-growth-strategy/

A panel of M&A advisors and consultants at CDMO Live 2025 explored how private equity investment has transformed the contract manufacturing sector, whilst examining current challenges from geopolitical uncertainty to market volatility. The session, sponsored by TH Healthcare & Life Sciences, featured Kurt Nielsen (Managing Partner, Longview Leader LLC), Dirk Beyer (Managing Director, Raymond James), Asif Shahinsha (Executive Director, TH Healthcare & Life Sciences), and Vishnu Dwadasi (Director Life Sciences, West Monroe).Download the full CDMO Live report

The biologics external manufacturing panel at CDMO Live 2025, sponsored by BSP Pharmaceuticals, brought together industry leaders to tackle the key challenges in scaling biological manufacturing amid geopolitical tensions, capacity constraints and evolving partnership models.The panel featured Olaf Birkenmeier, Head of External Manufacturing at Polpharma Biologics; Julien Laizé, Director of External Manufacturing CTM at Valneva; Catherine Seigneur, Senior Director of External Manufacturing Business Lead at UCB; and Giorgio Salciarini, Head of Sales - Technical Business Development at BSP Pharmaceuticals.Download the full CDMO Live Report

Joshi Venugopal, SVP and Head of Region for Novartis Gene Therapies, outlined three critical inflection points that will determine whether cell and gene therapy reaches its full potential at CDMO Live 2025The cell and gene therapy industry finds itself squarely in the middle of a classic Gartner hype cycle, according to Novartis gene therapy chief Joshi Venugopal. Speaking at CDMO Live 2025, Venugopal drew on Novartis's experience with the first two FDA-approved gene therapies to map where the industry stands today — and what it will take to reach the "plateau of productivity.""We had the opportunity to be the pioneers in introducing these innovative medicines in several countries, and sense the opportunities and challenges first hand," Venugopal told delegates in Rotterdam.Download the full CDMO Live report

At CDMO Live 2025, industry leaders Elisabeth Stampa (Medicines for Europe), Elena Barboni (Flamma) and Agneta Larhed (RegSmart Life Science) discussed how Europe's stringent new regulations could reshape the continent's pharmaceutical manufacturing landscape.Europe's pharmaceutical manufacturing sector faces an unprecedented challenge as new environmental regulations threaten to drive production offshore, whilst the Critical Medicines Act attempts to bring it back home. Industry leaders warn that razor-thin margins on generic medicines could lead to widespread product withdrawals if costs aren't carefully managed.Download the full CDMO Live report

“When you’re building something at the edge of science, it’s crucial to start with the problem, not the solution. My team has created 15 pharma startups using this approach, and 14 are still alive.” – Kerstin Papenfuss, Director of Pharma at Deep Science VenturesKerstin Papenfuss serves as the Director of Pharma at Deep Science Ventures, where she leads the creation and development of novel therapeutics for unmet medical needs. With a PhD in Tumour Immunology from Imperial College London and an MBA from Bayes Business School, Kerstin brings over a decade of experience in oncology, signal transduction, and pharmaceutical markets to her role building science-based startups from scratch.Kerstin explains why traditional approaches to biotech startup creation often fail and how working from first principles can lead to more successful, impactful ventures. Her experience spans working with entrepreneurs, academics, pharmaceutical companies, and disease charities to build companies that solve fundamental challenges in healthcare.Read the full article:https://pharmasource.global/content/podcast/building-biotechs-from-first-principles-deep-science-ventures-formula-for-science-based-innovation/

The COVID-19 pandemic demonstrated how pharmaceutical manufacturing timelines can be dramatically compressed while maintaining quality. At CDMO Live 2025, Fabrice Le Garrec shared lessons from the Lonza-Moderna vaccine scale-up, where "timeline meant lives."Here are his "10 Commandments" for fast-tracking emergency drug manufacturing.Dpwnload the full CDMO Live 2025 Report

Simon Kucher opened CDMO Live 2025 in Rotterdam by unveiling brand new research developed in partnership with PharmaSource.The comprehensive study, presented by Kaan-Fabian Kekec and Clarita Simon, mapped the evolving landscape of CDMO-sponsor partnerships based on insights from over 100 industry experts.Read more

CDMO Live 2025, a panel sponsored by Lifecore Biomedical brought together industry quality leaders to discuss how quality management can become a strategic enabler rather than a compliance burden. The panel featured Jackie Klecker (EVP Quality & Development Services, Lifecore Biomedical), Liesbeth Foesters (VP Head of External & Clinical Supply Quality, UCB), Stefan Bouckaert (Vice President External Supply Integration Quality, Johnson & Johnson), and Gwladys Mabonzo (Associate Director External Manufacturing Vaccines, MSD).Download the full 50 page report